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Abstract The most predominant co-stimulation pathway, which
is critical for T cell activation and proliferation, is the CD28-B7
pathway. The anti-CD28 monoclonal antibody (mAb) also
provides a co-stimulatory signal to T cells. In order to construct
a functional Fv fragment (complex of VH and VL domains) of
anti-CD28 antibody using a bacterial expression system, cDNA
encoding the variable regions of immunoglobulin from 15E8
hybridoma cells was cloned and expressed in Escherichia coli.
The Fv fragment was obtained as a soluble protein from the
periplasmic fraction and showed a binding pattern similar to
parental IgG. The Fv fragment induced proliferation of
peripheral blood mononuclear cells in the presence of anti-CD3
or anti-CD2 mAb and enhanced anti-tumor activity of anti-
MUC1Uanti-CD3 bispecific antibody when tested with lympho-
kine-activated killer cells with T cell phenotype. Thus, the anti-
CD28 Fv fragment will be promising not only for the study of co-
stimulation, but also for cancer immunotherapy. ß 2000 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
Activation of T cells initially occurs by the engagement of
the T cell receptor (TCR)/CD3 with an antigen/major histo-
compatibility complex complex. However, this ¢rst signal
alone cannot induce complete T cell activation, and the sec-
ondary signaling pathways are important for T cell activation
and prevention of T cell anergy. The most universally char-
acterized co-stimulatory molecule is CD28, whose ligands are
the B7-1 (CD80) and B7-2 (CD86) molecules on the antigen
presenting cells [1^3]. B7-CD28 co-stimulation in the presence
of TCR/CD3 signal results in the promotion of cell cycle
progression, an increase in cytokine production [4^6], up-reg-
ulation of interleukin (IL)-2 receptors [7^9] and T cell prolif-
eration [3,10]. This co-stimulatory signal is also delivered by
interaction between CD28 and anti-CD28 monoclonal anti-
body (mAb). Administration of anti-CD28 antibody in vivo
resulted in the induction of CD40 ligand expression on T cells
and also subsequent expansion of B cells [11]. Thus, CD28
signaling has a great in£uence on the systemic immune sys-
tem, and protein engineering of anti-CD28 antibody would be
an important step for further characterization of the CD28-B7
co-stimulatory pathway and anti-CD28 antibody-mediated
biotherapy.
Recent protein engineering technology has made the devel-
opment possible of recombinant antibodies suitable for diag-
nostics, therapy and industrial applications such as protein
puri¢cation or catalysis. Because of its smaller molecular
size, utilization of variable fragments of antibodies, i.e. Fv
(complex of VH and VL domains) or single chain Fv [12],
would be attractive. The small molecular size enables anti-
body fragments to exhibit unique characteristics, including
application as immunodiagnostic and immunotherapeutic re-
agents, due to better penetration into solid tumor tissues [13],
lower immunogenicity [14] and improved pharmacokinetics.
Furthermore, these recombinant antibody fragments are easily
produced in large quantities and at low-cost by an Escherichia
coli expression system, and functional investigation can be
performed by site-directed mutagenesis of the Fv fragment.
Here, we report the ¢rst successful construction of a bacterial
expression system for anti-CD28 Fv fragment and describe
the fragment’s functional characteristics.
2. Materials and methods
2.1. Oligodeoxyribonucleotide primers
Primers for mouse V-gene ampli¢cation by polymerase chain reac-
tion (PCR) were obtained from the Ig prime kit (Novagen). Other
primers used in this study were synthesized on an Applied Biosystem
model 391 DNA synthesizer and puri¢ed by polyacrylamide gel elec-
trophoresis (PAGE) under denatured conditions.
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2.2. mAbs and hybridoma cell lines
The anti-CD28 hybridoma cell line 15E8 (mouse IgG1) [15] was
kindly provided by Dr. R. van Lier (Central Laboratory of the Neth-
erlands Red Cross Blood Transfusion Service, Amsterdam, the Neth-
erlands). Two mAbs, TS2/18.1.1 (anti-CD2, mouse IgG1) and OKT3
(anti-CD3, mouse IgG2a), were obtained from the respective hybrid-
oma cells. The MUSE11 mAb, a mouse IgG1 directed at epithelial
mucin core protein 1 (MUC1) antigen [16], was used for preparation
of bispeci¢c antibody (bsAb).
2.3. cDNA synthesis, PCR ampli¢cation of variable region genes of
15E8 hybridoma
Total RNA was isolated from hybridoma 15E8 cells using Dyna-
beads oligo(dT) (Dynal) and the ¢rst strand cDNA synthesis was
performed using a ¢rst strand cDNA synthesis kit (Life Sciences).
PCR ampli¢cation of the heavy and light chain variable domain
(VH and VL) families was performed separately using an Ig prime
kit (Novagen). The ampli¢ed V-genes were cloned into TA vector
(Invitrogen), followed by DNA sequencing using the Auto Read Se-
quencing kit (Pharmacia) according to the recommendations of the
manufacturer.
2.4. Construction of 15E8 Fv co-expression vector
The cloned VH or VL genes were modi¢ed by introducing £anking
NcoI and SacII sites by PCR and inserted into pSNE4 vector [17],
which is a derivative of pGEM-2 (Promega). Thus, pSNE4-15E8 VH
(Fig. 1A) and pSNE4-15E8 VL (Fig. 1B) were constructed ¢rst. Next,
the gene fragment from rbs to the stop codon, including the 15E8 VL
gene in pSNE4-15E8 VL, was modi¢ed by introducing £anking Bam-
HI and SpeI sites by PCR and inserted into pSNE4-15E8 VH. The
gene was tandemly arranged with rbs-pelB-15E8 VH-rbs-pelB-15E8
VL, designated as pSNE4-15E8 Fv (Fig. 1C). This vector has two
kinds of C-terminal peptide tags: the c-myc peptide tag for detection
by 9E10 mAb (Santa Cruz Biotechnology) and the 6Uhistidine tag
for puri¢cation by metal-immobilized a⁄nity chromatography.
2.5. Expression of 15E8 Fv
For production of 15E8 Fv, the E. coli strain BL21 (DE3) trans-
formed with pSNE4-15E8 Fv was grown to the early stationary phase
at 28‡C in 2UYT broth supplemented with 100 Wg/ml ampicillin. To
induce the expression of 15E8 Fv, 1 mM isopropyl-1-thio-L-D-galac-
topyranoside was added and the cells were grown overnight. The bac-
terial supernatant (BS) fraction was obtained from the culture me-
dium by centrifugation (2000Ug, 35 min). The cell pellet was
resuspended in 10 ml of 20 mM Tris^HCl (pH 7.5), 0.5 M sucrose
and 0.1 mM EDTA, kept at room temperature for 5 min and then
40 ml of cold water was added in order to induce osmotic shock. The
suspension was kept on ice for 30 min and then centrifuged at
2000Ug for 35 min at 4‡C. The periplasmic (PP) fraction was ob-
tained from the supernatant.
2.6. Sodium dodecyl sulfate (SDS)^PAGE and Western blotting
The proteins in each fraction were precipitated with 6% trichloro-
acetic acid and 0.083% deoxycholate and then applied to SDS^PAGE
under reducing conditions as reported previously [18]. The proteins
were stained with Coomassie brilliant blue R-250. Next, proteins in
the gel were blotted to nitrocellulose membranes (Amersham-Pharma-
cia). Thereafter, the blots were incubated with peroxidase-conjugated
anti-His tag mAb (Santa Cruz Biotechnology) followed by signal en-
hancement using the ECL detection system (Amersham-Pharmacia).
2.7. Puri¢cation of soluble 15E8 Fv
Soluble fractions (BS and PP) were salted out with ammonium
sulfate at 70% saturation, and precipitates were collected by centrifu-
gation at 4500Ug for 20 min. The precipitates were dissolved in
phosphate-bu¡ered saline (PBS) (pH 7.9) overnight and dialyzed
with PBS (pH 7.9) for three times. They were puri¢ed with a TALON
metal a⁄nity resin column (Clontech) and eluted with three bu¡er
solutions made of sequentially increasing concentrations of imidazole
(1, 10 to 500 mM)/PBS. Minor impurities were removed by gel ¢ltra-
tion on a Superdex 75 pg column (Amersham-Pharmacia)
(1.0U100 cm), pre-equilibrated with PBS, pH 7.4.
2.8. Preparation of lymphokine-activated killer cells with T cell
phenotype (T-LAK)
T-LAK cells were prepared as reported previously [19]. Brie£y,
peripheral blood mononuclear cells (PBMCs) from healthy volunteers
were isolated by density gradient centrifugation and cultured for 48 h
in culture medium (RPMI 1640 supplemented with 10% fetal bovine
serum, 100 U/ml penicillin and 100 Wg/ml streptomycin) and 100 IU/
ml IL-2 (Shionogi Pharmaceutical Co. Ltd.) in a culture £ask pre-
coated with OKT3 mAb (10 Wg/ml). The proliferating cells were then
transferred to another £ask and allowed to expand for 2 weeks in the
culture medium containing 100 IU/ml IL-2.
2.9. Flow cytometry
T-LAK cells were incubated with puri¢ed 15E8 Fv (100 Wl) on ice
for 30 min. Cells were washed with 0.1% NaN3/PBS three times, and
then incubated with mouse anti-c-myc antibody (9E10) as the second-
ary antibody. Cells were stained with FITC-conjugated goat anti-
mouse IgG (Cappel Lab.) as the tertiary antibody. The stained cells
were analyzed by FACS Calibur (Becton Dickinson). For positive
control, 15E8 IgG was used as the ¢rst antibody and FITC-conju-
gated goat anti-mouse antibody as the second antibody.
2.10. Blockage of 15E8 IgG binding to T-LAK cells by 15E8 Fv
T-LAK cells were incubated with 50 Wl of puri¢ed 15E8 Fv
(0.28 mg/ml) on ice for 30 min. Next, 10 Wl of 15E8 IgG (0.1 mg/
ml) was added and incubated for 30 min to compete with 15E8 Fv
binding. The cells were washed with 0.1% NaN3/PBS three times
and stained with FITC-conjugated goat anti-mouse IgG to detect
15E8 IgG binding. The stained cells were analyzed by FACS Cali-
bur.
2.11. Proliferation assay of PBMCs
Proliferation of mitogen-activated human PBMCs was performed
using a Cell Proliferation enzyme-linked immunosorbent assay (ELI-
SA) system (Amersham Life Science Ltd.). Brie£y, 1U105 freshly
isolated PBMCs suspended in 0.2 ml culture medium were distributed
into each well of a 96-well £at-bottomed plate (Sumitomo Bakelite
Ltd.) in the presence of various concentrations of 15E8 Fv or 15E8
IgG together with anti-CD3 or anti-CD2 mAb. After incubation for
48 h at 37‡C, bromodeoxyuridine (BrdU) labeling reagent was added
and the cells were incubated for an additional 24 h. The detection
procedure was according to the manufacturer’s assay protocol for
suspension cells. The optical density was measured using a plate read-
er (Bio-Rad model 3550) at 450 nm.
2.12. Expression of CD25 on antibody-activated PBMCs
Freshly isolated 2U105 PBMCs suspended in 0.2 ml culture me-
dium were distributed into each well of a 96-well £at-bottomed plate
in the presence of OKT3 mAb or 15E8 Fv or their combination. After
72 and 96 h, cells were harvested, washed with 0.1% NaN3/PBS and
incubated with FITC-conjugated anti-IL-2R (CD25) mAb (Becton
Dickinson). After 30 min incubation on ice, the cells were washed
twice and analyzed for CD25 expression by FACS Calibur.
2.13. Cancer cell line
Human bile duct carcinoma cell line, TFK-1 [20], which is positive
for adenocarcinoma-associated antigen MUC1 [19], was used as the
target for growth inhibition assay.
2.14. Growth inhibition assay of cancer cells
E¡ectiveness of bsAb (anti-MUC1Uanti-CD3 bsAb) in speci¢c tar-
geting immunotherapy of cancer and production of the bsAb was
described in a previous report [19]. Growth inhibition assays of cancer
cells were performed using a MTS ((3-(4,5-dimethylthiazole-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazorium, inner salt)
assay kit (Promega Co.). Brie£y, 5000 target cells in 100 Wl culture
medium were distributed to each well of a half-area (A/2) 96-well £at-
bottomed plate (Costar Corp.) and cultured overnight. After remov-
ing the culture medium, 100 Wl of T-LAK cells, preincubated with
various concentrations of bsAb (anti-MUC1Uanti-CD3) [19] and
15E8 Fv for 30 min, was distributed into each well. After culture
for 48 h at 37‡C, each well was washed with PBS three times. This
was followed by the addition of MTS/phenazine methosulfate solution
(Promega Co.) diluted with culture medium. The plates were read on
a microplate reader at 490 nm after incubation for 1 h at 37‡C. The
growth inhibition of cancer cells was calculated as follows: % growth
inhibition of cancer cells = [13(A490 of experiment3A490 of back-
ground)/(A490 of control3A490 of background)]U100.
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3. Results
3.1. Cloning of variable domains of 15E8 anti-CD28 antibody
VH and VL genes of 15E8 hybridoma cells were ampli¢ed
by PCR using an Ig prime kit. Ampli¢ed V-genes were cloned
into TA vector and sequenced. Nucleotide and deduced amino
acid sequences of VH and VL clones are shown in Fig. 2. The
15 amino acid sequences from N-termini of each chain de-
duced from cloned DNA sequences were identical to the se-
quences analyzed from the parental IgG (data not shown). By
comparing the amino acid sequences with the Kabat’s data-
base (sixth edition) of immunoglobulin sequences, obtained
from the World Wide Web, the VL domain of 15E8 was
identi¢ed as a member of the mouse immunoglobulin kappa
chain subgroup V, and the VH domain as a member of the
heavy chain subgroup IIIc.
3.2. Expression and puri¢cation of 15E8 Fv
15E8 Fv was produced using E. coli strain BL21 (DE3)
harboring the plasmid pSNE4-15E8 Fv (Fig. 1C). We con-
¢rmed the expression of 15E8 Fv using SDS^PAGE (Fig.
3A) followed by Western blotting analysis using anti-His tag
mAb (Fig. 3B). Both 15E8 VH and 15E8 VL were secreted
into the PP and bacterial culture supernatant fractions. Under
reducing conditions, Fv separated into VH and VL, and two
bands could be detected corresponding to the calculated mo-
lecular weight of 16 500 Da for 15E8 VH and 15 200 Da for
15E8 VL. The soluble Fv was puri¢ed by immobilized metal
a⁄nity chromatography, followed by gel ¢ltration. Under gel
¢ltration, the puri¢ed Fv fragment has a molecular weight of
ca. 25 kDa (Fig. 4), indicating that the Fv fragment is a
hetero-dimer composed of a stoichiometric association of
VH with VL. Final yields of 15E8 Fv were about 4 mg
from 1 l culture.
3.3. Reactivity of 15E8 Fv for T-LAK cells
The reactivity of the 15E8 Fv was examined by £ow cyto-
metry. Puri¢ed soluble 15E8 Fv reacted with CD28-positive
T-LAK cells, showing a similar positive pattern to that of
parental 15E8 IgG (Fig. 5A).
In order to determine that this 15E8 Fv has the same anti-
body speci¢city as parental IgG, a blocking test was per-
formed and reactivity was examined by £ow cytometry. In
brief, T-LAK cells were incubated with 15E8 Fv as the ¢rst
competitor. Next, 15E8 IgG was added, and the binding of
Fig. 1. Schematic construction of 15E8 Fv expression vectors.
(A) 15E8 VH expression vector; (B) 15E8 VL expression vector;
(C) 15E8 Fv expression vector. The positions of primers and impor-
tant restriction sites used for constructing 15E8 Fv expression vec-
tors are shown. c-myc, a sequence encoding an epitope recognized
by the mAb 9E10; 6UHis, a sequence encoding six C-terminal histi-
dine residues; rbs, a sequence encoding the ribosome binding re-
gion.
Fig. 2. Nucleotide sequences and deduced amino acid sequences of the VH and VL regions of 15E8 hybridoma. Complementarity determining
regions 1, 2 and 3 are underlined.
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15E8 IgG was detected by FITC-conjugated anti-mouse IgG.
As shown in Fig. 5B, reactivity of 15E8 IgG was apparently
blocked by 15E8 Fv, indicating that 15E8 Fv has the same
antibody speci¢city as 15E8 IgG.
3.4. Proliferation of PBMCs stimulated by various mAbs
To assess the co-stimulatory function of the 15E8 Fv frag-
ment, two types of proliferation assays for PBMCs were per-
formed. The ¢rst used a combination of anti-CD3 mAb
OKT3 and 15E8 Fv, and the second used a combination of
anti-CD2 mAb TS2/18.1.1 and 15E8 Fv. In the presence of
OKT3 mAb (0.5 Wg/ml), proliferation of PBMCs was en-
hanced dose-dependently by 15E8 Fv. This activity of 15E8
Fv was almost equal to parental 15E8 IgG (Fig. 6A).
Fig. 6B shows the results of the combination of anti-CD2
mAb with 15E8 Fv. When 15E8 Fv alone was added to
PBMCs, enhancement of proliferation was very marginal. In
contrast to this, remarkable proliferation of PBMCs was ob-
served using a combination of 15E8 Fv and anti-CD2 mAb
(1.0 Wg/ml), indicating that 15E8 Fv fragment has a co-stim-
ulatory function.
3.5. Induction of activation marker (CD25) on PBMCs by
anti-CD3 mAb and 15E8 Fv
CD25 expression on PBMCs cultured in the presence of
di¡erent combinations of anti-CD3 mAb and 15E8 Fv was
tested by £ow cytometry (Fig. 7). Each mAb or Fv was used
at a concentration of 0.25 Wg/ml. OKT3 alone induced con-
siderable CD25 expression, which increased until 72 h, but
declined at 96 h. Induction of CD25 expression by 15E8
IgG or Fv alone was negligible. However, the combination
of OKT3 and 15E8 Fv (or 15E8 IgG) enhanced CD25 expres-
sion remarkably, maintaining it at a high level at 96 h.
3.6. Enhancement of anti-tumor activity of
anti-MUC1Uanti-CD3 bsAb by 15E8 Fv
In our previous study, we reported the usefulness of bsAb
in speci¢c targeting immunotherapy of cancer [19]. Therefore,
the co-stimulatory function of 15E8 Fv for cancer immuno-
Fig. 3. (A) SDS^PAGE and (B) Western blot of each fraction of E.
coli BL21 (DE3) cells expressed 15E8 Fv fragment. Lanes: 1, cul-
ture supernatant of Fv; 2, PP fraction of Fv. The positions of mo-
lecular size markers are shown on the left.
Fig. 4. Gel ¢ltration of 15E8 Fv. (A) 1 ml of proteins eluted from
immobilized metal a⁄nity chromatography was loaded at a £ow
rate of 0.5 ml/min. Under this condition, the retention time of the
standards is shown under the horizontal line. (B) SDS^PAGE of
the eluted fraction. The fraction indicated in (A) by the arrow has
been analyzed. Molecular size markers (kDa) are shown on the left.
Fig. 5. Reactivity of 15E8 Fv to T-LAK cells was examined by £ow
cytometry. (A) (a) T-LAK cells were incubated with 15E8 IgG (pri-
mary antibody), following FITC-conjugated anti-mouse IgG (sec-
ondary antibody). (b) T-LAK cells were ¢rst incubated with 15E8
Fv ¢rst, then anti-c-myc (9E10) mAb (secondary antibody). Finally,
cells were incubated with FITC-conjugated anti-mouse IgG as the
tertiary antibody. (c) PBS was used instead of the primary antibody
(15E8 Fv) as negative control. (B) Competition between 15E8 Fv
and IgG was examined by blocking test. The reactivity of 15E8 IgG
to T-LAK cells was examined by £ow cytometry. (a) T-LAK cells
were incubated with 15E8 IgG (as positive control), followed by
FITC-conjugated anti-mouse IgG. (b) T-LAK cells were incubated
with 15E8 Fv (primary antibody). Next, cells were incubated with
15E8 IgG. Finally FITC-conjugated anti-mouse IgG was added to
examine competition between 15E8 Fv and IgG. (c) T-LAK cells
were incubated with 15E8 Fv, followed by incubation with FITC-
conjugated anti-mouse IgG (negative control).
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therapy was examined by MTS growth inhibition assay of
cancer cells. MUC1-positive cell line TFK-1 cells were used
as the target and T-LAK cells as the e¡ector. At an e¡ector:-
target ratio of 5:1, the e¡ect of bsAb (anti-MUC1Uanti-CD3)
was enhanced dose-dependently by the addition of 15E8 Fv
(Fig. 8).
4. Discussion
The T cell-speci¢c receptor CD28 is an important regulator
of the immune system. CD28 strongly enhances T cell func-
tions, which are essential for an e¡ective antigen-speci¢c re-
sponse. The primary antigen signal alone cannot induce com-
plete T cell activation, and the second co-stimulation
pathway, interaction between B7 on the antigen presenting
cells [21,22] and CD28, is important for T cell activation
and proliferation. Since this co-stimulatory signal is also de-
livered by treatment with anti-CD28 antibody, development
of mass production methods of anti-CD28 antibody by gene
engineering is desirable. Toward this end, we tried to con-
struct the Fv fragment of anti-CD28 antibody (15E8 [15]).
15E8 Fv and parental IgG showed an identical binding
pattern (Fig. 5A) and the blocking test con¢rmed that both
recognized the same epitope of CD28 (Fig. 5B). 15E8 Fv
enhanced proliferation of PBMCs in the presence of anti-
CD3 mAb, as did its parental IgG (Fig. 6A). Similarly,
15E8 Fv also enhanced anti-CD2 activity as demonstrated
by proliferation of PBMCs (Fig. 6B). The co-stimulatory ac-
tivity of anti-CD28 mAb [23] was successfully imparted to
15E8 Fv. The function of 15E8 Fv was substantiated by the
enhanced IL-2 receptor (CD25) expression, wherein that 15E8
Fv plus anti-CD3 mAb induced lasting and enhanced expres-
Fig. 6. PBMC proliferation assay (72 h BrdU incorporation test). Freshly isolated PBMCs were incubated for 72 h with anti-CD3 mAb
(OKT3), anti-CD2 mAb (TS2/18.1.1), 15E8 Fv, 15E8 IgG or a combination of these antibodies. BrdU was then added to the culture. Incorpo-
ration of BrdU was measured for 72 h by Cell Proliferation ELISA system. (A) Combination of OKT3 mAb with 15E8 Fv. (B) Combination
of anti-CD2 mAb with 15E8 Fv. Data are mean values of triplicate determinations.
Fig. 7. Expression of CD25 (IL-2 receptor) on cultured PBMCs. Freshly isolated PBMCs (2U105/well) were cultured in the presence of OKT3
mAb, 15E8 Fv, 15E8 IgG or their combination. After 72 and 96 h, cells were harvested and stained with FITC-conjugated anti-CD25 mAb.
CD25 expression of the cells was analyzed by £ow cytometry.
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sion of IL-2 receptor (Fig. 7). Moreover, the e¡ect of this
functional co-stimulation by 15E8 Fv was re£ected in the
anti-tumor activity mediated by bsAb (Fig. 8). These results
clearly indicate that the Fv fragment exhibits signi¢cant co-
stimulatory activity, nearly equal to the parental 15E8 IgG.
Therefore, this 15E8 Fv can be applied in further studies, such
as the analysis of antibody-mediated co-stimulation by site-
directed mutagenesis of variable domains, or the construction
of recombinant bsAb, diabodies [24^26].
In conclusion, we have succeeded in constructing a bacterial
expression system for the anti-CD28 Fv fragment, which has
the same speci¢city and almost identical functional character-
istics as its parental anti-CD28 antibody. The Fv fragment
will be promising not only for study of co-stimulation, but
for cancer immunotherapy.
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Fig. 8. 15E8 Fv enhances anti-tumor activity of bsAb. TFK-1 cells
(target) and T-LAK cells (e¡ector) were cultured in the presence of
bsAb (anti-MUC1Uanti-CD3) (0.05 or 0.1 Wg/ml), with or without
15E8 Fv for 48 h. Each well was washed three times, and then
MTS/phenazine methosulfate solution was added. After 60 min, the
microplate was read on a microplate reader at 490 nm. E:T ra-
tio = 5:1. Data are mean values of triplicate determinations.
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